Drug Profile

NI 308

Alternative Names: NI-308

Latest Information Update: 28 Dec 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Neurimmune Therapeutics
Developer Biogen; Neurimmune Therapeutics
Class Antidementias; Monoclonal antibodies
Mechanism of Action Immunomodulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

No development reported Amyotrophic lateral sclerosis; Dementia

Most Recent Events

28 Dec 2024 No recent reports of development identified for preclinical development in Amyotrophic-lateral-sclerosis in Switzerland
28 Dec 2024 No recent reports of development identified for preclinical development in Dementia in Switzerland
07 Dec 2022 NI 308 is still in preclinical trials for Amyotrophic-lateral-sclerosis and Dementia in Switzerland (Neurimmune pipeline, December 2022)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com